September 22, 2017 — Today, Aegerion Pharmaceuticals Inc. agreed to plead guilty in the United States District Court for the District of Massachusetts to two misdemeanor counts of violating the Federal Food, Drug, and Cosmetic Act (FD&C Act)…Original Article
You may also like
Ariane de Ganck
Jasper Therapeutics merges with Kira Pharmaceuticals
Lilly to acquire AtaiBeckley in deal worth $2.8bn
Camena Bioscience appoints Gregory McGuinness as CEO
New €25 Million BioReliance Testing Facility Opens...
StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
